From the publishers of JADPRO
Updates for the Advanced Practitioner
Multiple Myeloma
Subscribe
About
Contact
MENU
Home
Visit JADPRO Online
In The News
In The Literature
Videos
More Updates
Advertisement
In The News
American Society of Hematology 2016 Annual Meeting
Session 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I
American Society of Hematology 2016 Annual Meeting
Session 653. Myeloma: Therapy, excluding Transplantation: IMiD/Proteasome Inhibitor Combinations and Maintenance Therapy
American Society of Hematology 2016 Annual Meeting
Abstract 1143: Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study
American Society of Hematology 2016 Annual Meeting
Abstract 673: Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)
American Society of Hematology 2016 Annual Meeting
Abstract 537: Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect® MM Disease Registry
The ASCO Post
ESMO 2016 Abstract 55PD: Vemurafenib (VM) in non-melanoma V600 and non-V600 BRAF mutated cancers: First results of the ACSE trial
ESMO
ESMO 2016 Abstract 940TiP - Pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM): randomized, phase 3 KEYNOTE-185 study
ESMO
ESMO 2016 Abstract 941TiP - Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study
ESMO
ESMO 2016 Abstract 906O - Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR
The ASCO Post
Study Finds Statin Use Associated With Reduced Mortality in Multiple Myeloma
The ASCO Post
Meta-Analysis Shows Association of Minimal Residual Disease–Negative Status With Improved Survival in Multiple Myeloma
Janssen
Janssen Submits Application to U.S. FDA to Expand Indication for Daratumumab (DARZALEX®)
The ASCO Post
Adding Daratumumab to Bortezomib/Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma
The ASCO Post
Autologous Stem Cell Transplant May Age Immune Cells as Much as 30 Years
ASCO
2016 ASCO Annual Meeting Abstract 8010: Pembrolizumab in Combination With Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Final Efficacy and Safety Analysis
The ASCO Post
FDA Grants Breakthrough Therapy Designation for Daratumumab in Combination With Standard of Care for Multiple Myeloma
ASCO
2016 ASCO Annual Meeting Abstract 8059: Healthcare Costs Among Multiple Myeloma (MM) Patients (Pts) Without Stem Cell Transplant (SCT)
ASCO
2016 ASCO Annual Meeting Abstract 6517: Patients´ Competence in Oral Cancer Therapies
ASCO
2016 ASCO Annual Meeting Abstract 8007: Phase 1/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM): A Multiple Myeloma Research Consortium Multicenter Study
ASCO
2016 ASCO Annual Meeting Abstract 8001: Lenalidomide (LEN) Maintenance (MNTC) After High-Dose Melphalan and Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma (MM): A Meta-Analysis (MA) of Overall Survival (OS)
ASCO
2016 ASCO Annual Meeting Abstract LBA4: Phase III Randomized Controlled Study of Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR Study
The ASCO Post
Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial
The ASCO Post
Kenneth Anderson, MD, on Multiple Myeloma Guideline Updates
The ASCO Post
Sagar Lonial, MD, and Paul G. Richardson, MD, on Multiple Myeloma
The ASCO Post
Antonio Palumbo, MD, on Multiple Myeloma: Results From the CASTOR Trial
The ASCO Post
Adding Daratumumab to Bortezomib and Dexamethasone Markedly Improves Outcomes in Recurrent/Refractory Multiple Myeloma
The ASCO Post
Expert Point of View: Paul G. Richardson, MD
The ASCO Post
Benefits and Risks of Transplantation: The Changing Therapeutic Paradigm for Multiple Myeloma: A Conversation With Paul G. Richardson, MD
The ASCO Post
Study Links Radon Exposure to Increased Risk of Hematologic Malignancies in Women
The ASCO Post
Tight Junction Protein 1 May Identify Sensitivity to Proteasome Inhibitors in Patients With Multiple Myeloma
Reuters
Independent Group Finds Multiple Myeloma Drugs Too Costly in US
The ASCO Post
Geriatric Assessment of Transplant-Ineligible Older Adults With Multiple Myeloma: A Novel Approach in the Era of Novel Agents
The ASCO Post
Carfilzomib Plus Dexamethasone in Previously Treated Multiple Myeloma
The ASCO Post
CAR-T Cell Therapy May Have a Role in Treating Multiple Myeloma
ScienceDaily
New Therapeutic Target in Myeloma Discovered
The ASCO Post
FDA Approves Carfilzomib as Single Agent or in Combination in Relapsed/Refractory Multiple Myeloma
The ASCO Post
Studies Confirm and Extend the Benefits of Ixazomib in Multiple Myeloma
The ASCO Post
Study Confirms Benefit of Triplet vs Doublet in Newly Diagnosed Multiple Myeloma
The ASCO Post
Elotuzumab in Previously Treated Multiple Myeloma
The ASCO Post
Multiple Myeloma in 2015: A Year for the Record Books
Blood
Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777
Blood
Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up
The ASCO Post
ASH 2015: Updated Results of the Phase I/II GEN503 Study of Daratumumab in Multiple Myeloma
The ASCO Post
Better Quality of Life With Melphalan and Prednisone Used With Lenalidomide Than With Thalidomide
The ASCO Post
Impressive Results With Daratumumab Plus Lenalidomide/Dexamethasone in Multiple Myeloma
Myeloma UK
Highlights from the 15th International Myeloma Workshop
The ASCO Post
FDA Accepts for Priority Review the Biologics License Application for Elotuzumab for the Treatment of Relapsed Multiple Myeloma
The ASCO Post
MMRF Announces Enrollment Completion of CoMMpass Study
The ASCO Post
NCCN Unveils Graphic Evidence Blocks to Guide Decision-Making
The ASCO Post
FDA Approves Daratumumab for Patients With Previously Treated Multiple Myeloma
Videos
Perspectives on the Collaborative Management of Multiple Myeloma
Advertisement
In The News
American Society of Hematology 2016 Annual Meeting
Session 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I
American Society of Hematology 2016 Annual Meeting
Session 653. Myeloma: Therapy, excluding Transplantation: IMiD/Proteasome Inhibitor Combinations and Maintenance Therapy
American Society of Hematology 2016 Annual Meeting
Abstract 1143: Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study
American Society of Hematology 2016 Annual Meeting
Abstract 673: Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)
American Society of Hematology 2016 Annual Meeting
Abstract 537: Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect® MM Disease Registry
View all >
In The Literature
Br J Haematol.
Elotuzumab in combination with thalidomide and low-dose dexamethasone
Leukemia
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents
Bone Marrow Transplant
Autologous stem cell transplant for multiple myeloma patients 70 years or older
Ann Hematol.
Observational study of multiple myeloma in Latin America
J Clin Oncol
Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma
View all >
Videos
Perspectives on the Collaborative Management of Multiple Myeloma
Advertisement
Copyright © 2019 Harborside Press, LLC All rights reserved.
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our
Privacy Policy
to learn more.